CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

被引:17
|
作者
Guegan, Jean-Philippe [1 ]
Pollet, Justine [2 ]
Ginestier, Christophe [3 ]
Charafe-Jauffret, Emmanuelle [3 ]
Peter, Marcus E. [4 ]
Legembre, Patrick [5 ]
机构
[1] Explicyte, Cours Argonne, F-33000 Bordeaux, France
[2] Univ Limoges, Technol Core Facil BISCEm, CHU Limoges, US042,Inserm,UMS CNRS 2015, Limoges, France
[3] Aix Marseille Univ, CNRS, INSERM, Inst Paoli Calmettes,CRCM Mol Oncol Equipe Labell, Marseille, France
[4] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Univ Limoges, UMR CNRS 7276, CRIBL, INSERM 1262, Limoges, France
关键词
SIGNALING PATHWAY; NITRIC-OXIDE; SOMATIC MUTATIONS; FAS LIGAND; PROTEIN; EXPRESSION; GENE; RECEPTOR; CELLS; APOPTOSIS;
D O I
10.1016/j.isci.2021.103538
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CD95 expression is preserved in triple-negative breast cancers (TNBCs), and CD95 loss in these cells triggers the induction of a pro-inflammatory program, promoting the recruitment of cytotoxic NK cells impairing tumor growth. Herein, we identify a novel interaction partner of CD95, Kip1 ubiquitination-promoting complex protein 2 (KPC2), using an unbiased proteomic approach. Independextly of CD95L, CD95/KPC2 interaction contributes to the partial degradation of p105 (NF-kappa B1) and the subsequent generation of p50 homodimers, which transcriptionally represses NF-kappa B-driven gene expression. Mechanistically, KPC2 interacts with the C-terminal region of CD95 and serves as an adaptor to recruit ReIA (p65) and KPC1, which acts as E3 ligase promoting the degradation of p105 into p50. Loss of CD95 in TNBC cells releases KPC2, limiting the formation of the NF-kappa B inhibitory homodimer complex (p50/p50), promoting NF-kappa B activation and the production of pro-inflammetory cytokines, which might contribute to remodeling the immune landscape in TNBC cells.
引用
收藏
页数:21
相关论文
共 50 条
  • [21] Carboxy-terminal domain of CD95 suppresses anti-CD95 antibody mediated but not CD95L mediated
    Thilenius, ARB
    Russell, JH
    FASEB JOURNAL, 1996, 10 (06): : 408 - 408
  • [22] NFκB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis
    Zender, L
    Kühnel, F
    Paul, Y
    Trautwein, C
    Kubicka, S
    Manns, MP
    JOURNAL OF HEPATOLOGY, 2000, 32 : 161 - 161
  • [23] NFκB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis
    Kühnel, F
    Zender, L
    Paul, Y
    Tietze, MK
    Trautwein, C
    Manns, M
    Kubicka, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (09) : 6421 - 6427
  • [24] CD95 (Fas)-induced caspase-mediated proteolysis of NF-κB
    Ravi, R
    Bedi, A
    Fuchs, EJ
    Bedi, A
    CANCER RESEARCH, 1998, 58 (05) : 882 - 886
  • [25] Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism
    Nabipour, Iraj
    Kalantarhormozi, Mohammadreza
    Assadi, Majid
    Jafari, Seyed Mojtaba
    Gharibi, Mohammad
    Ahmadi, Esmaeil
    Sanjdideh, Zahra
    ENDOCRINE, 2010, 38 (03): : 406 - 411
  • [26] Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism
    Iraj Nabipour
    Mohammadreza Kalantarhormozi
    Majid Assadi
    Seyed Mojtaba Jafari
    Mohammad Gharibi
    Esmaeil Ahmadi
    Zahra Sanjdideh
    Endocrine, 2010, 38 : 406 - 411
  • [27] IL-2 induces Fas ligand Fas (CD95L/CD95) cytotoxicity in CD8(+) and CD4(+) T lymphocyte clones
    Esser, MT
    Dinglasan, RD
    Krishnamurthy, B
    Gullo, CA
    Graham, MB
    Braciale, VL
    JOURNAL OF IMMUNOLOGY, 1997, 158 (12): : 5612 - 5618
  • [28] CD95L/CD95 GENE DELETION DECREASES MOUSE GLIOMA TUMORIGENESIS THROUGH THE INHIBITION OF NON-CANONICAL CD95L/CD95-MEDIATED CELL GROWTH AND IMMUNOSUPPRESSION
    Quijano-Rubio, Clara
    Weller, Michael
    NEURO-ONCOLOGY, 2021, 23 : 37 - 38
  • [29] MECHANISM OF HIPPOCAMPAL CD95/CD95L AND BDNF/TRKB PATHWAY IN THE DEVELOPMENT OF TRIGEMINAL NEURALGIA IN RATS
    Deng, Ruyun
    ACTA MEDICA MEDITERRANEA, 2022, 38 (03): : 2147 - 2151
  • [30] Modification of tumor cells with Fas (CD95) antigen gene and Fas ligand (CD95L) gene transfection by electroporation for immunotherapy of cancer
    Shimizu, M
    Yoshimoto, T
    Matsuzawa, A
    Takeda, Y
    MOLECULAR BIOTECHNOLOGY, 2003, 25 (01) : 79 - 87